Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638564 | 0.93 | F2 (0.48) | F2TFPINPBWR1NTSR1NTSR2 | |
| SCHEMBL13634057 | 0.85 | F2 (0.55) | F2NTSR1NTSR2OPRD1 | |
| SCHEMBL13633986 | 0.85 | NPY4R (0.58) | F2NTSR1NTSR2 | |
| SCHEMBL31307237 | 0.84 | GLP1R (0.53) | F2GLP1R | |
| SCHEMBL18234195 | 0.84 | KISS1R (0.49) | F2TFPIOPRD1GLP1R | |
| SCHEMBL29702389 | 0.83 | TFPI (0.54) | F2TFPINPBWR1NTSR1NTSR2 | |
| SCHEMBL13633962 | 0.82 | F2 (0.52) | F2TFPINTSR1NTSR2OPRD1 | |
| SCHEMBL13634094 | 0.82 | BACE1 (0.55) | F2TFPINTSR1NTSR2OPRD1 | |
| SCHEMBL29702470 | 0.82 | TFPI (0.54) | F2TFPINPBWR1OPRD1GLP1R | |
| SCHEMBL30567448 | 0.81 | TFPI (0.59) | F2TFPIGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | F2 1249/4885TFPI 183/4885NPBWR1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.